baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Cara Therapeutics Inc/ US1407551092 /

2024-04-25 10:00:00 PM	Chg. +0.0284	Volume	Bid1:22:20 AM	Ask1:22:20 AM	High	Low
0.7000USD	+4.23%	319,087 Turnover: 199,266.9985	0.6722Bid Size: 1,000	0.7060Ask Size: 400	0.7168	0.6400

GlobeNewswire 04-24 Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer

GlobeNewswire 04-02 Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire 03-07 Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

GlobeNewswire 03-04 Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 02-12 Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

GlobeNewswire 01-22 Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into ...

GlobeNewswire 2023-12-18 Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelik...

GlobeNewswire 2023-11-13 Cara Therapeutics Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-02 Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Roy...

GlobeNewswire 2023-10-23 Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023

GlobeNewswire 2023-09-25 Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of ...

GlobeNewswire 2023-09-05 Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire 2022-03-28 Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers ...

GlobeNewswire 2022-03-08 Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentati...

GlobeNewswire 2022-03-01 Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2022-02-25 Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...

GlobeNewswire 2022-02-22 Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

GlobeNewswire 2022-02-18 Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

GlobeNewswire 2022-01-10 Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in ...

GlobeNewswire 2022-01-03 Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2021-12-20 Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

GlobeNewswire 2021-11-18 Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire 2021-11-09 Cara Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire 2021-11-08 Cara Therapeutics Reports Third Quarter 2021 Financial Results

GlobeNewswire 2021-11-03 Cara Therapeutics Announces CEO Transition

Cara Therapeutics Inc/ US1407551092 /

If you wish to receive reply to your feedback, please provide your email address.